GLP-1 Costs & Employer Metabolic Risk — What's Shifting | 2026
GLP-1 Costs & Employer Metabolic Risk — What's Shifting | 2026 There's a particular conversation happening in benefits strategy meetings at mid-size and large American companies that would have been nearly unimaginable just five years ago. Not the conversation about rising healthcare costs — that one has been a fixture of every benefits planning cycle for more than a decade, grinding along with the familiar 7% to 9% annual escalation that actuaries have been projecting and employers have been absorbing with varying degrees of equanimity. The new conversation is different in character. It's faster, more uncertain, and considerably more expensive per line item than anything the pharmacy benefits landscape has seen in a generation. The conversation is about GLP-1 receptor agonists — the class of medications originally developed for type 2 diabetes management that exploded into the weight-loss market with results striking enough to reshape both popular culture and e...